Grups d'Investigació

GIUV2013-082

No Determinada

• Desenvolupament de noves formes farmaceutiques que controlen l'absorcio de farmacs (fonamentalment per sistemes de cessio modificada) a traves de pell, ull i intesti, i els estudis farmacocinetics associats. Utilitzacio de l'administracio topica com a via d'optimitzacio de la seguretat. Adaptacio de les tecniques d'avaluacio biofarmaceutica de sistemes cololoidals. Prediccio "in silico".

• Design of materials for drug targeting and cosmetic use.The excipients used to transport active substances (both in therapeutics and cosmetics) are not inert. They can promote or delay absorption and, as such, they shape the bioavailability in speed and magnitude of the molecules of interest. It is very important to validate this role in order to optimise the form of administration. Two objectives delimit the line: on the one hand, to describe the effect of the most commonly used vehicles and, on the other hand, to prepare nuts that improve the capacity to increase or decrease absorption depending on the systemic or topical target, respectively. The research group collaborates with other institutions (University of Saarland-Germany and University of Rio Grande do Sul-Brazil, mainly) in the preparation and characterisation of the vehicles. It is responsible for the release studies and the mathematical modelling of the kinetics, which allows the optimisation of the material. It also carries out stability studies.
• Modeling in silico (QSAR) in drug design.In the early stages of drug development, it is very important to apply tools that minimise the use of animals due to ethical considerations and are also an alternative to reduce the cost of studies. With the understanding provided by the group's track record, LADME process modelling techniques are a very important strategy to identify the substances with the best biopharmaceutical properties among large series of compounds. They are based on molecular descriptors that can be derived mathematically. At the same time, they allow targeting modifications of bioactive molecules that simultaneously lead to interesting changes as drugs (reduced toxicity, increased solubility in biological fluids, increased stability).
• Drug absorption through intestinal mucosae, lung epitelia, eye and skin. Excipient influence. Biopharmaceutical assessment..Understanding the absorption process is an indisputable way to effectively modulate the bioavailability of drugs and to achieve optimisation of the dosage form. The line comprises in vitro and in vivo studies of absorption of different substances, in free solution and in the presence of additives. The process is characterised kinetically to infer the mechanisms underlying the absorption of pharmacologically active molecules and to describe, at a later stage, the effect produced by the excipients of the dosage forms. The conclusions are tested by bioavailability studies. The ultimate aim is to describe strategies for vectoring the drug to the target tissue, in adequate quantity and speed for optimal effect, while reducing distribution to the rest of the body, leading to reduced side effects and improved safety.

• -
• -

• Pharmacy and Pharmaceutical Technology

• nanocarriers, liposomes, colloids, targeting, polimeric nanoparticles, solid-lipid nanoparticles, bioavailability, controlled drug release, polymeric films, microneedles, drug safety
• Modeling, in silico, QSAR, drug, design
• oral administration, intestinal absorption, skin penetration, lung bioavailability, drugs, excipients, polymeric films, microneedles